Powers of the Likelihood Ratio Test and the Correlation Test Using Empirical Bayes Estimates for Various Shrinkages in Population Pharmacokinetics

We compared the powers of the likelihood ratio test (LRT) and the Pearson correlation test (CT) from empirical Bayes estimates (EBEs) for various designs and shrinkages in the context of nonlinear mixed‐effect modeling. Clinical trial simulation was performed with a simple pharmacokinetic model with various weight (WT) effects on volume (V). Data sets were analyzed with NONMEM 7.2 using first‐order conditional estimation with interaction and stochastic approximation expectation maximization algorithms. The powers of LRT and CT in detecting the link between individual WT and V or clearance were computed to explore hidden or induced correlations, respectively. Although the different designs and variabilities could be related to the large shrinkage of the EBEs, type 1 errors and powers were similar in LRT and CT in all cases. Power was mostly influenced by covariate effect size and, to a lesser extent, by the informativeness of the design. Further studies with more models are needed.

[1]  Michel Tod,et al.  Evaluation of Uncertainty Parameters Estimated by Different Population PK Software and Methods , 2007, Journal of Pharmacokinetics and Pharmacodynamics.

[2]  France Mentré,et al.  Bayesian design criteria: Computation, comparison, and application to a pharmacokinetic and a pharmacodynamic model , 1995, Journal of Pharmacokinetics and Biopharmaceutics.

[3]  France Mentré,et al.  Prediction of Shrinkage of Individual Parameters Using the Bayesian Information Matrix in Non-Linear Mixed Effect Models with Evaluation in Pharmacokinetics , 2013, Pharmaceutical Research.

[4]  R. Savic,et al.  Importance of Shrinkage in Empirical Bayes Estimates for Diagnostics: Problems and Solutions , 2009, The AAPS Journal.

[5]  M. Karlsson,et al.  Shrinkage in Nonlinear Mixed-Effects Population Models: Quantification, Influencing Factors, and Impact , 2012, The AAPS Journal.

[6]  Peter J. Bickel,et al.  An Approximate Likelihood Approach to Nonlinear Mixed Effects Models Via Spline Approximation , 2003, Comput. Stat. Data Anal..

[7]  Leonid Gibiansky,et al.  Comparison of Nonmem 7.2 estimation methods and parallel processing efficiency on a target-mediated drug disposition model , 2011, Journal of Pharmacokinetics and Pharmacodynamics.

[8]  Stephen B. Duffull,et al.  Prospective Evaluation of a D-Optimal Designed Population Pharmacokinetic Study , 2003, Journal of Pharmacokinetics and Pharmacodynamics.

[9]  Jakob Ribbing,et al.  Power, Selection Bias and Predictive Performance of the Population Pharmacokinetic Covariate Model , 2004, Journal of Pharmacokinetics and Pharmacodynamics.

[10]  Wenbin Lu,et al.  Estimation and selection of complex covariate effects in pooled nested case-control studies with heterogeneity. , 2013, Biostatistics.

[11]  Julie Bertrand,et al.  Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithm , 2009, Journal of Pharmacokinetics and Pharmacodynamics.

[12]  Lewis B. Sheiner,et al.  Building population pharmacokineticpharmacodynamic models. I. Models for covariate effects , 1992, Journal of Pharmacokinetics and Biopharmaceutics.

[13]  D. Balding,et al.  Multiple single nucleotide polymorphism analysis using penalized regression in nonlinear mixed-effect pharmacokinetic models , 2013, Pharmacogenetics and genomics.

[14]  France Mentré,et al.  Performance Comparison of Various Maximum Likelihood Nonlinear Mixed-Effects Estimation Methods for Dose–Response Models , 2012, The AAPS Journal.

[15]  Goonaseelan Pillai,et al.  Non-Linear Mixed Effects Modeling – From Methodology and Software Development to Driving Implementation in Drug Development Science , 2005, Journal of Pharmacokinetics and Pharmacodynamics.

[16]  France Mentré,et al.  Sparse-Sampling Optimal Designs in Pharmacokinetics and Toxicokinetics* , 1995 .

[17]  Gerald A. Edgar,et al.  Problems and Solutions , 2015, Am. Math. Mon..

[18]  France Mentré,et al.  Fisher information matrix for non‐linear mixed‐effects models: evaluation and application for optimal design of enoxaparin population pharmacokinetics , 2002, Statistics in medicine.

[19]  France Mentré,et al.  Design evaluation and optimisation in multiple response nonlinear mixed effect models: PFIM 3.0 , 2010, Comput. Methods Programs Biomed..

[20]  E. Niclas Jonsson,et al.  The lasso—a novel method for predictive covariate model building in nonlinear mixed effects models , 2007, Journal of Pharmacokinetics and Pharmacodynamics.

[21]  Brian Whiting,et al.  Experimental design and efficient parameter estimation in population pharmacokinetics , 1990, Journal of Pharmacokinetics and Biopharmaceutics.

[22]  Peter L. Bonate.  Covariate Detection in Population Pharmacokinetics Using Partially Linear Mixed Effects Models , 2005, Pharmaceutical Research.